Выход
Вход/Login
 
E-mail
Пароль/Password
Забыли пароль?
Введите E-mail и жмите тут. Пароль будет выслан на указанный адрес
Войти (LogIn)

 

Если вы первый раз здесь, то зарегистрируйтесь

Регистрация/Sign Up
Полное имя (Ф.И.О.)/Name
E-mail
Телефон/Phone
Зарегистрироваться,
на ваш E-mail будет выслан временный пароль

 

Медицинская литература. Новинки


 

 

 

 

 

 
вce журналы << Медицинская визуализация << 2015 год << №2 <<
стр.110
отметить
статью

История развития контрастного усиления при ультразвуковом исследовании

Кармазановский Г. Г., Степанова Ю. А., Аскерова Н. Н.
Вы можете загрузить полный текст статьи в формате pdf
Кармазановский Григорий Григорьевич - доктор мед. наук, профессор, заведующий отделом лучевых методов диагностики и лечения ФГБУ “Институт хирургии им. А.В. Вишневского” МЗ РФ; профессор кафедры лучевой диагностики ИПО ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” МЗ РФ, ФГБУ “Институт хирургии им. А.В. Вишневского” Минздрава России; ГБОУ ВПО “Первый Московский государственный медицинский университет им. И.М. Сеченова” Минздрава России, karmazanovsky@yandex.ru, 119997 Москва, ул. Большая Серпуховская, 27
Степанова Юлия Александровна - доктор мед. наук, старший научный сотрудник отдела лучевых методов диагностики и лечения ФГБУ “Институт хирургии им. А.В. Вишневского” МЗ РФ; профессор кафедры лучевой диагностики ИПО ГБОУ ВПО “Первый МГМУ им. И.М. Сеченова” МЗ РФ, ФГБУ “Институт хирургии им. А.В. Вишневского” Минздрава России; ГБОУ ВПО “Первый Московский государственный медицинский университет им. И.М. Сеченова” Минздрава России, Москва, Россия
Аскерова Нурия Нураддиновна - ординатор отделения ультразвуковых методов диагностики и лечения, ФГБУ “Институт хирургии им. А.В. Вишневского” Минздрава России, Москва, Россия

УЗИ является неотъемлемой составной частью современной лучевой диагностики и в отечественной клинической медицине относится к наиболее широко используемым методам медицинской визуализации. На сегодняшний день в мировой клинической практике использование эхоконтрастных препаратов при УЗИ стало обязательным условием исследований больных любого клинического профиля при постоянном совершенствовании и разработке новых эхоконтрастных препаратов. В обзоре освещены основные физико-технические принципы контрастной ультразвуковой диагностики, достоинства и недостатки применяемых эхоконстрастных препаратов.

Ключевые слова:
ультразвуковое исследование, контрастное усиление, история развития, ultrasound, contrast enhancement, history of development

Литература:
1.Фомина С.В., Завадовская В.Д., Юсубов М.С. и др. Контрастные препараты для ультразвукового исследования. Бюллетень сибирской медицины. 2011; 6: 137-142.
2.Kleffel T. Comparison of contrast-enchanced lomechanical index sonography and unenenchanced B-mode sonography for the differentation between synovitis and joint effusion in patients with rheumatoid arthritis. Fortschr Roentgenstrahlen. 2005; 177: 835-841.
3.Lencioni R. Enhancing the role of ultrasound with contrast Agents. Springer-Verlag, Italia. 2009.
4.Quasia E. Microbubblebultrasound contrast agents: an up-date. Eur. Radiol. 2007; 17 (8): 1995-2008.
5.Jean-Michel C., Lori B., Amelie L. et al. Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. Eur. Radiol. 2001; 11: 1316-1328.
6.Brown A., Calachanis M., Evdoridis C. et al. Sonovue improves endocardial border detection and variability in assessing wall motion score and ejection fraction during stress echocardiography. Ir. J. Med. Sci. 2004; 173 (1): 13-17.
7.von Bibra H., Hartmann F., Petrik M. et al. Contrast-color Doppler echocardiography. Improved right heart diagnosis following intravenous injection of Echovist. Z. Kardiol. 1989; 78 (2): 101-108.
8.Rovai D., Lombardi M., Cini G. et al. Echocardiographic contrast imaging of the human right heart: a multicenter study of the efficacy, safety, and reproducibility of intravenous SHU-454. J. Clin. Ultrasound. 1991; 19 (9): 523-530.
9.Droste D.W., Silling K., Stypmann J. et al. Contrast transcranial doppler ultrasound in the detection of right-to-left shunts: time window and threshold in microbubble numbers. Stroke. 2000; 31 (7): 1640-1645.
10.Droste D.W., Jekentaite R., Stypmann J. et al. Contrast transcranial Doppler ultrasound in the detection of right-to-left shunts: comparison of Echovist-200 and Echovist-300, timing of the Valsalva maneuver, and general recommendations for the performance of the test. Cerebrovasc. Dis. 2002; 13 (4): 235-241.
11.el Mouaaouy A., Naruhn M., Becker H.D., Schlief R. Intraoperative echo-contrast ultrasound examination of malignant liver neoplasms-initial clinical experience. Surg. Endosc. 1991; 5 (4): 214-218.
12.Schlief R., Bauer A. Ultrasound contrast media. New perspectives in ultrasound diagnosis. Radiologe. 1996; 36 (1): 51-57.
13.Langholz J., Schlief R., Schurmann R. et al. Contrast enhancement in leg vessels. Clin. Radiol. 1996; 51, Suppl. 1: 31-34.
14.Miszalok V., Fritzsch T., Wollensak J. Contrast echography of the eye and orbit. Ophthalmologica. 1986; 193 (4): 231-235.
15.Venezia R., Zangara C. Echohysterosalpingography: new diagnostic possibilities with S HU 450 Echovist. Acta Eur Fertil. 1991; 22 (5): 279-282.
16.Ayida G., Harris P., Kennedy S. et al. Hysterosalpingo-contrast sonography (HyCoSy) using Echovist-200 in the outpatient investigation of infertility patients. Br. J. Radiol. 1996; 69 (826): 910-913.
17.Korell M., Seehaus D., Strowitzki T., Hepp H. Radiologic versus ultrasound fallopian tube imaging. Painfulness of the examination and diagnostic reliability of hysterosalpingography and hysterosalpingo-contrast-ultrasonography with Echovist 200. Ultraschall Med. 1997; 18 (1): 3-7.
18.Schlief R., Staks T., Mahler M. et al. Successful opacification of the left heart chambers on echocardiographic examination after intravenous injection of a new saccharide based contrast agent. Echocardiography. 1990; 7: 61-64.
19.Strunk H., Stuckmann G., Frohlich E. et al. Native and signal-enhanced power Doppler sonography for characterization of liver lesions. Rofo. 1998; 168 (4): 344-351.
20.Imai H., Horiguchi Y., Kubo H. et al. Color Doppler signal enhancement with SH/TH-508 in pancreatic tumors. Nihon Rinsho. 1998; 56 (4): 1018-1023.
21.Gebel M., Caselitz M., Bowen-Davies P.E., Weber S. A multicenter, prospective, open label, randomized, controlled phase IIIb study of SH U 508 a (Levovist) for Doppler signal enhancement in the portal vascular system. Ultraschall Med. 1998; 19 (4): 148-156.
22.Камалов Ю.Р., Сандриков В.А., Гаврилов А.В. Использование ультразвукового контраста Levovist при обследовании больных опухолями печени, портальной гипертензией и при ортотопической трансплантации печени. Клиническая физиология. Диагностика - новые методы; Под. ред. Сандрикова В.А. М.: Аир-Арт, 1998. 144-149.
23.Щербакова С.В., Кунцевич Г.И., Чебышева Э.Н. и др. Оценка результатов исследования кровотока у больных хронических панкреатитом и раком поджелудочной железы с помощью Левовиста. Клиническая физиология. Диагностика - новые методы; Под. ред. Сандрикова В.А. М.: Аир-Арт, 1998. 149-150.
24.Kratzer W., Kachele V., Merkle E. et al. Contrast enhanced power Doppler sonography: comparison of various administration forms of the ultrasound contrast agent Levovist. Rofo. 2000; 172 (5): 443-448.
25.Bernatik T., Becker D., Neureiter D. et al. Detection of liver metastases-comparison of contrast-enhanced ultrasound using first versus second generation contrast agents. Ultraschall. Med. 2003; 24 (3):175-179.
26.Chiba Y. Enhanced ultrasonography in the diagnosis of renal tumors. Nihon Rinsho. 1998; 56 (4): 1030-104.
27.Kim A.Y., Kim S.H., Kim Y.J., Lee I.H. Contrast-enhanced power Doppler sonography for the differentiation of cystic renal lesions: preliminary study. J. Ultrasound Med. 1999; 18 (9): 581-588.
28.Ascenti G., Zimbaro G., Mazziotti S. et al. Doppler power with contrast media in the characterization of renal masses. Radiol. Med. 2000; 100 (3): 168-174.
29.Kawauchi A., Hashimoto Y., Kamiya K. et al. Contrast echo imaging on the breast and thyroid cancers. Nihon. Rinsho. 1998; 56 (4): 1049-1054.
30.Guazzaroni M., Cossu E., Danese V. et al. Use of SHU 508 A Levovist contrast media in the characterization of solid lesions of the breast. Radiol. Med. 1998; 96 (1-2): 35-41.
31.Gruner C., Schonwalder A., Schulz-Wendtland R. et al. What is the role of Doppler color sonography associated with echo-signal enhancing levovist in complementary breast diagnosis? Aktuelle Radiol. 1998; 8 (2): 58-62.
32.Lagalla R., Caruso G., Urso R. et al. The correlations between color Doppler using a contrast medium and the neoangiogenesis of small prostatic carcinomas. Radiol. Med. 2000; 99 (4): 270-275.
33.Szymanski M., Szymanski W., Grabiec M., Korenkiewicz J. Evaluation of using Levovist in the differential diagnosis of ovarian tumors. Ginekol. Pol. 1999; 70 (6): 444-449.
34.Coppola V., Vallone G., Verrengia D. et al. Doppler color ultrasonography with contrast media in the study of eye and orbit neoplasms. Radiol. Med. 1997; 93 (4): 367-373.
35.Correas J., Quay S. EchoGen emulsion: a new ultrasound contrast agent based on phase shift colloids. Clin. Radiol. 1996; 51: 11-14.
36.Forsberg F., Roy R., Merton D. et al. Conventional and hypobaric activation of an ultrasound contrast agent. Ultrasound Med. Biol. 1998; 24: 1143-1150.
37.Lopez-Ben R., Robbin M.L., Weber T.M. et al. Doppler sonographic enhancement of hepatic hemangiomas and hepatocellular carcinomas after perflenapent emulsion: preliminary study. J. Ultrasound Med. 1999; 18 (2): 109-116.
38.Albrecht T., Patel N., Cosgrove D.O. et al. Enhancement of power Doppler signals from breast lesions with the ultrasound contrast agent EchoGen emulsion: subjective and quantitative assessment. Acad. Radiol. 1998; Suppl 5. 56. 1: S195-S198.
39.Ragde H., Kenny G.M., Murphy G.P., Landin K. Transrectal ultrasound microbubble contrast angiography of the prostate. Prostate. 1997; 32 (4): 279-283.
40.Totaro R., Del Sette M., Marini C. Echocontrast agents in neurosonology. Funct. Neurol. 1999; 14 (4): 235-239.
41.Rachdi R., Kasdaoui B., Messaoudi F. et al. The approach diagnoses of ovarian tumors by echography. Tunis. Med. 2005; 83 (12): 764-769.
42.Wilson S.R., Burns P.N., Muradali D. et al. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis. Radiology. 2000; 215 (1): 153-161.
43.Jung E.M., Clevert D.A., Rupp N. Contrast-enhanced ultrasound with Optison in percutaneous thermoablation of liver tumors. Rofo. 2003; 175 (10): 1403-1412.
44.Jung E.M., Kubale R., Jungius K.P. et al. Vascularization of liver tumors - preliminary results with Coded Harmonic Angio (CHA), phase inversion imaging, 3D power Doppler and contrast medium-enhanced B-flow with second generation contrast agent (Optison). Clin. Hemorheol. Microcirc. 2006; 34 (4): 483-497.
45.Becker D., Strobel D., Bernatik T., Hahn E.G. Echoenhanced color- and power-Doppler EUS for the discrimination between focal pancreatitis and pancreatic carcinoma. Gastrointest. Endosc. 2001; 53 (7): 784-789.
46.Jung E.M., Jungius K.P., Rupp N. et al. Contrast enhanced harmonic ultrasound for differentiating breast tumors - first results. Clin. Hemorheol. Microcirc. 2005; 33 (2): 109-120.
47.Forsberg F., Piccoli C.W., Merton D.A. et al. Breast lesions: imaging with contrast-enhanced subharmonic US-initial experience. Radiology. 2007; 244 (3): 718-726.
48.Rangasetty U.C., Martinez J.D., Ahmad M. Images in cardiovascular medicine. Contrast-enhanced echocardiography in spindle cell sarcoma of the pericardium. Circulation. 2007; 115 (11): e329-e331.
49.Broillet A., Puginier J., Ventrone R. et al. Assessment of myocardial perfusion by intermittent harmonic power Doppler using SonoVue, a new ultrasound contrast agent. Invest. Radiol. 1998; 33 (4): 209-215.
50.Kaps M., Seidel G., Bokor D. et al. Safety and ultrasoundenhancing potentials of a new sulfur hexafluoride-containing agent in the cerebral circulation. J. Neuroimaging. 1999; 9 (3): 150-154.
51.Lindner J., Wei K., Kaul S. Imaging of Myocardial Perfusion with SonoVuetrade mark in Patients with a Prior Myocardial Infarction. Echocardiography. 1999; 16 (7, Pt 2): 753-760.
52.Bogdahn U., Holscher T., Rosin L. et al. Contrast-Enhanced Transcranial and Extracranial Duplex Sonography: Preliminary Results of a Multicenter Phase II/III Study with SonoVue trade mark. Echocardiography. 1999; 16 (7, Pt 2): 761-766.
53.Rovai D., Morales M., Amyot R. et al. Clinical experience with SonoVue in myocardial perfusion imaging. Echocardiography. 2000; 17 (6, Pt 2): 17-23.
54.Madjar H., Prompeler H., Del Favero C. et al. A new Doppler signal enhancing agent for flow assessment in breast lesions. Eur. J. Ultrasound. 2000; 12 (2):123-130.
55.SonoVue International non-proprietary name: sulfur hexafluoride. Assessment report. Ed. Committee for Medicinal Products for Human Use (CHMP). UK: EMA, 2014; 1-33.
56.Albrecht T., Blomley M., Bolondi L. et al. Guidelines for the use of contrast agents in ultrasound. Ultraschall. Med. 2004; 25 (4): 249-256.
57.Claudon M., Cosgrove D., Albrecht T. et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) - update 2008. Ultraschall. Med. 2008; 29 (1): 28-44.
58.Claudon M., Dietrich C., Choi B. et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med. Biol. 2013; 39 (2): 187-210.
59.Piscaglia F., Nolsoe C., Dietrich C. et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med. 2012; 33 (1): 33-59.
60.Aneta D., Jacek R., Joanna K. et al. The Effect of Contrast Medium SonoVue on the Electric Charge Density of Blood Cells. J. Membrane Biol. 2012; 245: 15-22.
61.Blomley M., Cooke J. Unger E., et al. Microbubble contrast agents: a new era in ultrasound. BMJ. 2001; 322 (7296): 1222-1225.
62.Burns P., Wilson S. Microbubble contrast for radiological imaging: Principles. Ultrasound Q. 2006; 22 (1): 5-13.
63.Bolondi L., Correas J., Lencioni R. et al. New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Dig. Liver Dis. 2007; 39 (2): 187-195.
64.Piscaglia F., Lencioni R., Sagrini E. et al. Characterization of focal liver lesions with contrast-enhanced ultrasound. Ultrasound Med. Biol. 2010; 36 (4): 531-550.
65.Morel D., Schwieger I., Hohn L. et al. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest. Radiol. 2000; 35 (1): 80-85.
66.Larsson M., Nowak G., Paradossi G. et al. Endocardial border delineation capability of a novel multimodal polymer-shelled contrast agent. Cardiovasc. Ultrasound. 2014; 12: 24.
67.Bokor D., Chambers J., Rees P. et al. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest. Radiol. 2001; 36 (2): 104-109.
68.Jakobsen J., Oyen R., Thomsen H. et al. Safety of ultrasound contrast agents. Eur. Radiol. 2005; 15 (5): 941-945.
69.Piscaglia F., Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med. Biol. 2006; 32 (9): 1369-1375.
70.Gaibazzi N., Squeri A., Ardissino D. et al. Safety of contrast flash-replenishment stress echocardiography in 500 patients with a chest pain episode of undetermined origin within the last 5 days. Eur. J. Echocardiogr. 2009; 10 (6): 726-732.
71.Brenner D., Hall E. Computed tomography - an increasing source of radiation exposure. N. Engl. J. Med. 2007; 357 (22): 2277-2284.
72.Wilson S., Greenbaum L., Goldberg B. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? Am. J. Roentgenol. 2009; 193 (1): 55-60.
73.Beaton C., Cochlin D., Kumar N. Contrast enhanced ultrasound should be the initial radiological investigation to characterise focal liver lesions. Eur. J. Surg. Oncol. 2010; 36 (1): 43-46.
74.De Castro S., Agati L., Cartoni D. Harmonic imaging with Levovist for transthoracic echocardiographic reconstruction of left ventricle in patients with post-ischemic left ventricular dysfunction and suboptimal acoustic windows. J. Am. Soc. Echocardiogr. 2000; 13 (2): 139-145.
75.Цвибель В.Дж., Пеплерито Д.С. Ультразвуковое исследование сосудов; Под ред. В.В. Митькова, Ю.Н. Никитина, Л.В. Осипова: пер. с англ. В.В. Борисенко, Е.И. Кремневой, М.И. Киселёвой и др. М.: Видар-М, 2008. 646 с.
76.Лелюк В.Г., Лелюк С.Э. Ультразвуковая ангиология. М.: Реальное время. 1999. 288 с.
77.De Castro S., Agati L., Cartoni D. Harmonic imaging with Levovist for transthoracic echocardiographic reconstruction of left ventricle in patients with post-ischemic left ventricular dysfunction and suboptimal acoustic windows. J. Am. Soc. Echocardiogr. 2000; 13 (2): 139-145.
78.Greis C. Contrast-Enhanced Ultrasound in General Imaging. Springer-Verlag, 2005.
79.Bertolotto M. Value of contrast - enhanced ultrasonography for detecting renal infarcts proven by contrast enhanced CT. A feasibility study. Eur. Radiol. 2008; 18: 376-383.
80.Correas J.M. Contrast - enhanced ultrasonography: renal applications. J. Radiol. 2003; 84: 2041-2054.

History of Development of Contrast-Enhanced Imaging at Ultrasound

Karmazanovsky G. G., Stepanova Y. A., Askerova N. N.

Ultrasonic research is the integral component of modern radiodiagnosis and in domestic clinical medicine belongs to the most widely used methods of medical visualization. Use the contrast agents at ultrasonic research became an indispensable condition of researches of patients of any clinical profile at continuous improvement and development new the contrast agents in world clinical practice today. The basic physics and technology principles of contrast ultrasonic diagnostics, merits and demerits of the preparations applied the contrast agents are covered in the review.

Keywords:
ультразвуковое исследование, контрастное усиление, история развития, ultrasound, contrast enhancement, history of development

ООО Издательский дом ВИДАР-М, 2016